CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...
Key takeways: Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for pathology AI lies in personalized medicine with big data. Better characterization of the patient...
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with the 2018 Global Technology Innovation Award. Each year,...
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Education and Early CareerJordyn received his Bachelor of Science in Community Health Sciences at the University of Nevada-Reno. Jordyn always wanted to be in the medical field, either in patient care or in medicine. According to an old yearbook, he actually wanted to...
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True ValueBy Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and Roberto GiananiDigital pathology’s benefits have been widely discussed –...
OverviewDuring a recent panel discussion, members of the Flagship Biosciences team and representatives from The Johns Hopkins University, Leap Therapeutics, and Corritori Consulting shared their thoughts on companion diagnostics development, with an emphasis on...
EVENTS
Visit Flagship at SITC | Booth #818.November 8-12, 2022.Stop by our booth to meet our new CSO Tom Turi, Ph.D., and talk with us about how we can partner with you for end-to-end biomarker support. Come learn about our new services, and pick up a map of our favorite...
Visit Flagship at World CB & CDx | Booth #4. Boston, MA | September 26-29, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support and see our latest data. Assay development and validation Clinical trial support...
Visit Flagship at AACR | Booth #1554. April 8-13, 2022. Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support, see our latest data from this year’s featured posters, and pick up a map of our favorite NOLA eateries. Assay...